Webinar: Strategic Pharmacovigilance Activities. Scalable and Tailor-made Outsourcing Models
Larger companies often limit their strategic pharmacovigilance activities outsourcing only to highly manual and repetitive tasks, while the smaller ones may want to outsource their entire pharmacovigilance system. But is there anything in between?
- How can larger companies benefit from outsourcing strategic pharmacovigilance activities while maintaining full control and compliance?
- How can small/medium-sized companies get access to a serious pharmacovigilance database that grows with them without having to break the bank?
- What are the advantages of scalable and tailor-made outsourcing models?
- How can the pharmaceutical companies obtain benefits from the scalability and standardization required to ensure central oversight while also retaining local effectiveness?
You will learn about strategic pharmacovigilance activities outsourcing through scalable and tailor-made outsourcing models and how it can be done in a controlled way:
1. Full pharmacovigilance outsourcing
- What does it mean?
- How will you remain in control?
2. Outsourcing a pharmacovigilance database
- How to select a proper database?
- How to get access to it without buying it yourself?
- What control levels can you opt for?
3. Outsourcing specific strategic pharmacovigilance activities
- How to remain in control?
Optimizing your pharmacovigilance activities?
Make use of our experts’ invaluable know-how in managing pharmacovigilance activities while remaining in control.
Who should attend?
- Global QPPVs / Deputies
- QPPV Office managers
- Heads of Pharmacovigilance
- Heads of Pharmacovigilance Technologies
- Drug Safety Managers
- Drug Safety Leaders involved in Risk Management, Aggregate Safety reports, Oversight and Standards
Duration: 50 min.
Speakers:
- Head of Global Pharmacovigilance, Martijn van de Leur;
- International QPPV, Olga Asimaki;
- QPO Manager and Head of Pharmacovigilance Technologies, Gediminas Zvicevičius.
Martijn van de Leur, MSc
Head of Global Pharmacovigilance
Other content that might interest you:
Saudi FDA’s New Pricing Guidelines and Impact on the Region
In a highly evolving regional pricing environment, Saudi Arabia (KSA) is no exception. The Saudi Food and Drug Authority (SFDA) has been periodically reviewing its pricing mechanisms and criteria so that the country becomes a regional reference for the prices of pharmaceutical products. What followed is a change in the pricing strategy by SFDA and a shift from price takers to price makers.
Marketing pharmaceutical products in CIS countries / Eurasion Union
The interest of pharmaceutical companies in expanding business across CIS region has been constantly growing. For the same reason, Biomapas has expanded presence and now covers the whole CIS region, providing core services: clinical research, regulatory affairs,...
Regulatory Strategy in the EAEU and rest of CIS Countries
Webinar: Regulatory Strategy in the EAEU and Rest of CIS Countries Regulatory strategy in EAEU and CIS regions differ from other regions as market access to these countries can be a real challenge due to various local regulations. However, it is only a matter of...
